FDA approve satralizumab for neuromyelitis optica spectrum disorder (NMSOD)

Approval of this humanised monoclonal antibody inhibitor of interleukin-6 receptor activity, was based on data from the SAkuraStar and SAkuraSky studies, in which satralizumab demonstrated efficacy and safety in adults with AQP4 antibody positive NMOSD.

Source:

PharmaTimes